Abstract
Glial cell line-derived neurotrophic factor (GDNF) has been postulated as a possible candidate for therapeutic treatment in Parkinson’s disease (PD). Recent in vitro data suggest that 1,25-dihydroxyvitamin D3 [1,25(OH) 2D 3] treatment may enhance GDNF mRNA expression. In the present study, using semiquantitative RT-PCR and Western blot, we have shown that 1,25(OH) 2D 3 administration intraperitoneally, significantly increases GDNF mRNA and protein levels in the striatum of adult rats.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
